aTyr Pharma Lead‑Plaintiff Deadline Hits as Rival Firms Vie to Steer Securities Case
Plaintiff jockeying stems from a Phase 3 miss that preceded an 83% one‑day stock collapse.
Overview
- Investor notices from Hagens Berman, the Schall Law Firm and Rosen Law Firm urged aTyr shareholders to move for lead‑plaintiff appointment by Dec. 8.
- Complaints allege aTyr and its executives misled investors about Efzofitimod’s efficacy, focusing on claims the drug could enable complete steroid tapering.
- Hagens Berman framed its proposed class period as Nov. 7, 2024 through Sept. 12, 2025, while Schall cited Jan. 16, 2025 through Sept. 12, 2025.
- The EFZO‑FIT Phase 3 study failed its primary endpoint tied to reducing mean daily oral corticosteroid dose, according to the filings.
- aTyr shares fell about 83% in a single day on Sept. 15, 2025, and firms note no class has been certified and investors are not yet represented unless they retain counsel.